Tendon Recovery Protocol
The canonical BPC-157 + TB-500 healing stack for tendon, ligament, and soft-tissue injury — phased dose schedule with cited mechanism rationale.
TL;DR
Run 500 mcg–1 mg BPC-157 daily (1 mg/day at the injury site for acute repair) plus 2.5–5 mg TB-500 SubQ 2× weekly for 4–6 weeks loading, then 2.5 mg TB-500 weekly maintenance. BPC-157 drives local angiogenesis and growth-factor sensitization; TB-500 mobilizes progenitor cells to the wound. Stack works because the mechanisms are complementary, not redundant.
Compounds
BPC-157 + TB-500
Route
Subcutaneous (both)
BPC-157 dose
500 mcg–1 mg daily (1 mg/day baseline)
TB-500 dose
2.5–5 mg, 2× weekly (loading); 2.5 mg weekly (maintenance)
Acute phase
Continuous BPC-157 + TB-500 4–6 wk loading
Maintenance
BPC-157 daily continues; TB-500 drops to weekly
Who this protocol is for
- Acute tendon or ligament injury (Achilles, rotator cuff, ACL, MCL)
- Chronic tendinopathy that has plateaued with PT alone
- Post-surgical soft-tissue recovery
- Athletes returning from overuse injuries (tennis elbow, jumper's knee)
- Joint capsule injuries (hip, shoulder labrum)
Why this stack
Pick a single compound and you cover half the repair cascade. BPC-157 is the local actor — it drives angiogenesis (new blood vessels at the injury) and upregulates growth-hormone receptor expression on fibroblasts, so the cells in the area become more responsive to repair signals. But BPC-157 doesn't deliver new cells to the site.
TB-500 is the systemic actor. It binds G-actin and mobilizes stem and progenitor cells from bone marrow, sending them toward sites of injury or inflammation. But TB-500 doesn't build the vascular network those cells need to operate in.
Stack both and you get the full repair pipeline: BPC-157 builds the highway and primes the local environment; TB-500 dispatches the construction crew. The mechanisms are complementary, not redundant, which is why this stack is the canonical orthopedic injury protocol in practitioner medicine.
Phase schedule
Phase 1
Weeks 1–6: Acute healing
Aggressive phase. Both compounds at full dose. The goal is to flood the injury site with angiogenesis signals (BPC) and mobilize progenitor cells (TB) while inflammation is still active.
- BPC-157: 1 mg subQ daily (canonical injury-site dose — single daily injection near the lesion when feasible).
- TB-500: 2.5–5 mg subQ, twice weekly (e.g. Mon + Thu). Inject anywhere subQ — distributes systemically.
Phase 2
Weeks 7–12: Continued acute / extended loading
BPC-157 continues at the same daily dose — repair is faster with continuous signaling. TB-500 drops to weekly maintenance dose; the cell-mobilization phase is complete by week 6.
- BPC-157: 500 mcg–1 mg subQ daily (continue until functional load testing passes).
- TB-500: 2.5 mg subQ, once weekly (maintenance).
Phase 3
Weeks 11+: Off-cycle
Stop both. Re-evaluate at week 14. If tendon is still symptomatic at full load testing, consider a second 4-week cycle after at least 4 weeks off. Don't run the stack continuously — there's no published long-term safety data and receptor sensitivity is preserved by cycling.
- No injections. Re-test functional load at week 14.
- If symptoms persist: 4-week wash → repeat acute phase.
Step-by-step setup
- Source pharmaceutical-grade peptides. Both compounds should come from a supplier with HPLC and mass-spec verification. Avoid 'research chemical' suppliers without third-party COAs. Janoshik testing is the practitioner standard.
- Reconstitute BPC-157. Add 2 mL of bacteriostatic water to a 5 mg lyophilized vial. Result: 2.5 mg/mL (2500 mcg/mL). On a 100-unit insulin syringe, 10 units = 250 mcg. 20 units = 500 mcg.
- Reconstitute TB-500. Add 2 mL of bacteriostatic water to a 5 mg lyophilized vial. Result: 2.5 mg/mL. On a 100-unit insulin syringe, 80 units = 2.0 mg. 100 units = 2.5 mg.
- Inject BPC-157 twice daily. Morning and evening. Subcutaneous in the abdomen or thigh. Rotate injection sites to prevent local irritation. When the injury is accessible (Achilles, forearm), some practitioners inject near the site.
- Inject TB-500 twice weekly. Subcutaneous, anywhere with adequate fat pad. TB-500 distributes systemically — proximity to injury doesn't matter the way it can with BPC-157. Common schedule: Monday + Thursday.
- Track baseline + weekly progress. Baseline pain (0–10), range of motion, and a functional test specific to the injury (e.g. single-leg calf raise for Achilles). Re-test weekly. Expect noticeable improvement by week 3.
- Pair with PT, not in place of it. The protocol amplifies repair, but it doesn't replace progressive loading. Continue physical therapy throughout. Most practitioners see the best outcomes when peptides + PT run in parallel.
Expected outcomes
- Pain reduction typically noticeable by week 2–3
- Range of motion improvement by week 4
- Functional load tolerance restored by week 6–8 in most cases
- Reduced reliance on NSAIDs during the acute phase
- Many practitioners report faster return-to-sport than PT-alone protocols
Safety + side-effect profile
The BPC + TB stack has a favorable real-world safety profile in practitioner reports but lacks long-term published human safety data. Cycle on/off; do not run continuously.
- Injection-site irritation: occasional redness, itching, transient bruising. Rotate sites.
- BPC-157 head-pressure or flushing: occasional in week 1, usually resolves with dose split.
- TB-500 first-dose fatigue: occasional 'flu-like' fog from systemic immune activation, resolves after 1–2 doses.
- Avoid during active malignancy — both modulate growth-factor and angiogenesis pathways.
- Pregnancy/breastfeeding: not appropriate — no safety data.
- Always source pharmaceutical-grade peptides with HPLC/mass-spec verification.
Frequently asked
Can I run BPC-157 alone instead of the full stack?
Yes, for milder injuries — BPC-157 alone produces meaningful tendon and ligament improvement, especially when injected near the injury site. The full stack outperforms monotherapy for moderate-to-severe injuries because TB-500 adds a cell-delivery mechanism BPC-157 doesn't have. If cost or injection burden is a constraint, BPC-157 alone is a reasonable starting point.
How fast should I expect results?
Pain reduction is usually noticeable by week 2–3. Range of motion typically improves by week 4. Full functional load tolerance returns by week 6–8 for most acute injuries. Chronic injuries (tendinopathies that have been present >6 months) often need a second 4-week cycle after a wash period.
Do I have to inject BPC-157 near the injury?
Not strictly. Standard subQ injection in the abdomen produces systemic effects. But many practitioners inject near accessible injury sites (Achilles, forearm, elbow) because BPC-157's angiogenic effect appears stronger locally. For deeper or hard-to-reach injuries, abdominal injection works fine.
Can I run this protocol with NSAIDs?
You can, but it may blunt the response. NSAIDs reduce the inflammation that BPC-157 and TB-500 are partially leveraging as a repair signal. Most practitioner protocols recommend minimizing NSAIDs during the acute phase and using ice + acetaminophen for pain control instead. Discuss with your clinician.
Is this protocol safe with surgery?
Many surgeons recommend stopping peptides 1–2 weeks before any surgical procedure due to angiogenesis and bleeding-risk considerations, then resuming once incision healing is established (typically week 2–3 post-op). Always disclose to your surgical team.
Cited research
Sikiric et al. — Brain–gut axis and pentadecapeptide BPC 157. Curr Neuropharmacol 2016.
Chang et al. — Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 2014.
Goldstein et al. — Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005.
Crockford et al. — Thymosin beta-4: structure, function, and biological properties. Ann N Y Acad Sci 2010.
Personalize this protocol with the Coach
The Coach adapts dose, timing, and side-effect mitigation to your bloodwork, body comp, and goals — and outputs a cited PDF protocol card you can take to your doctor.
Ask the Coach